128 related articles for article (PubMed ID: 24729221)
1. Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors.
Khan N; Hou H; Hodge S; Kuppusamy M; Chen EY; Eastman A; Kuppusamy P; Swartz HM
Adv Exp Med Biol; 2014; 812():105-111. PubMed ID: 24729221
[TBL] [Abstract][Full Text] [Related]
2. Tumor pO₂ as a surrogate marker to identify therapeutic window during metronomic chemotherapy of 9L gliomas.
Mupparaju S; Hou H; Lariviere JP; Swartz HM; Khan N
Adv Exp Med Biol; 2011; 701():107-13. PubMed ID: 21445776
[TBL] [Abstract][Full Text] [Related]
3. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
Mupparaju S; Hou H; Lariviere JP; Swartz H; Jounaidi Y; Khan N
Oncol Rep; 2011 Jul; 26(1):281-6. PubMed ID: 21503586
[TBL] [Abstract][Full Text] [Related]
4. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
[TBL] [Abstract][Full Text] [Related]
5. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
[TBL] [Abstract][Full Text] [Related]
6. Effect of a topical vasodilator on tumor hypoxia and tumor oxygen guided radiotherapy using EPR oximetry.
Hou H; Abramovic Z; Lariviere JP; Sentjurc M; Swartz H; Khan N
Radiat Res; 2010 May; 173(5):651-8. PubMed ID: 20426665
[TBL] [Abstract][Full Text] [Related]
7. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Francia G; Shaked Y; Hashimoto K; Sun J; Yin M; Cesta C; Xu P; Man S; Hackl C; Stewart J; Uhlik M; Dantzig AH; Foster FS; Kerbel RS
Mol Cancer Ther; 2012 Mar; 11(3):680-9. PubMed ID: 22188817
[TBL] [Abstract][Full Text] [Related]
8. Repeated assessment of orthotopic glioma pO(2) by multi-site EPR oximetry: a technique with the potential to guide therapeutic optimization by repeated measurements of oxygen.
Khan N; Mupparaju S; Hou H; Williams BB; Swartz H
J Neurosci Methods; 2012 Feb; 204(1):111-117. PubMed ID: 22079559
[TBL] [Abstract][Full Text] [Related]
9. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.
Cham KK; Baker JH; Takhar KS; Flexman JA; Wong MQ; Owen DA; Yung A; Kozlowski P; Reinsberg SA; Chu EM; Chang CW; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Yapp DT; Ng SS
Br J Cancer; 2010 Jun; 103(1):52-60. PubMed ID: 20531411
[TBL] [Abstract][Full Text] [Related]
10. Modulation of tumor hypoxia by topical formulations with vasodilators for enhancing therapy.
Abramovic Z; Hou H; Julijana K; Sentjurc M; Lariviere JP; Swartz HM; Khan N
Adv Exp Med Biol; 2011; 701():75-82. PubMed ID: 21445772
[TBL] [Abstract][Full Text] [Related]
11. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
12. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Ciccolini J; Barbolosi D; Meille C; Lombard A; Serdjebi C; Giacometti S; Padovani L; Pasquier E; André N
Cancer Res; 2017 Sep; 77(17):4723-4733. PubMed ID: 28655786
[TBL] [Abstract][Full Text] [Related]
14. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo.
Senkal CE; Ponnusamy S; Rossi MJ; Sundararaj K; Szulc Z; Bielawski J; Bielawska A; Meyer M; Cobanoglu B; Koybasi S; Sinha D; Day TA; Obeid LM; Hannun YA; Ogretmen B
J Pharmacol Exp Ther; 2006 Jun; 317(3):1188-99. PubMed ID: 16510697
[TBL] [Abstract][Full Text] [Related]
15. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
16. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
17. Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy.
Hou H; Lariviere JP; Demidenko E; Gladstone D; Swartz H; Khan N
Radiother Oncol; 2009 Apr; 91(1):126-31. PubMed ID: 19013657
[TBL] [Abstract][Full Text] [Related]
18. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
[TBL] [Abstract][Full Text] [Related]
19. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
20. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.
Eisbruch A; Shewach DS; Bradford CR; Littles JF; Teknos TN; Chepeha DB; Marentette LJ; Terrell JE; Hogikyan ND; Dawson LA; Urba S; Wolf GT; Lawrence TS
J Clin Oncol; 2001 Feb; 19(3):792-9. PubMed ID: 11157033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
